An interventional study of Blood pressure intervention arm in Hypertension and Rheumatoid Arthritis, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Duke University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Hypertension by Duke University — 8 open to participants now, 9 under way, none of them phase 3. Hypertension · Duke University.
Among the 46 studies in Hypertension by Duke University, this one is the 32nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2026, is one of 34 with no phase, and was the 37th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →8 of the 46 studies in Hypertension by Duke University are open now, in 2 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18–75 · Healthy volunteers
Duke University · Sites in United States
Ages 6–14 · Healthy volunteers
Duke University · Sites in United States, Canada
Ages 0–20 · Healthy volunteers
Duke University · Sites in United States
Ages 12–17 · Healthy volunteers
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 140 across the 37 interventional studies, 1,000 across the 8 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
6 of the studies in Hypertension by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT05459077Duke UniversityAddressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression | 2026-12-30 |
| NCT05760898Duke UniversityImproving Hypertension Control in Rheumatoid Arthritis | 2026-12-31 |
| NCT04454203Duke UniversityFemoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension | 2027-02-01 |
| NCT06595251Duke UniversityCommunity Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study | 2027-05-17 |
Add all 6 to your calendar (.ics) → With an account.
Among the 46 studies in Hypertension by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rheumatoid arthritis (RA) is a autoimmune disease associated with an increased risk of developing coronary artery disease (CAD) and premature death,. Traditional CAD risk factors like hypertension (HTN) are both very common and poorly controlled among RA patients. Patients with RA face significant challenges in controlling HTN. The goal of this project is to identify barriers to HTN care in patients with RA to reduce CAD events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The investigators will recruit 25 RA patients with HTN for the study. Participants will be provided with a home blood pressure monitor, teaching from nursing staff regarding the correct use of the monitor, and a guide to help interpret normal and elevated blood pressure values. Participants will be instructed to obtain and record blood pressure values at least three times per week over the course of 3 months. Every 2 weeks, these results will be sent to the study team, and participants will complete a brief survey regarding other factors that may influence blood pressure control, including RA disease activity (RAPID3 score), pain, current use of acute RA therapies, anti-hypertensive medication use, anti-hypertensive medication adherence, and current perceived barriers to HTN self-management.
Behavioral: Blood pressure intervention arm
The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.
Intervention feasibility as measured by participant accrual rates
Rate at which participants are able to be successfully recruited
Time frame: 6 months
Intervention feasibility as measured by participant retention
Percentage of participants who successfully complete the study
Time frame: 6 months
Intervention feasibility as measured by adherence to blood pressure monitoring
Percentage of expected blood pressures reported by participants
Time frame: 6 months
Intervention feasibility as measured by adherence to survey reporting
Percentage of expected surveys completed by participants
Time frame: 6 months
Intervention feasibility as measured by sample characteristics
Description of sociodemographic characteristics of population, rheumatoid arthritis characteristics (eg, duration, medications, severity), and hypertension characteristics (eg, duration, medications, severity)
Time frame: 6 months
Intervention feasibility as measured by use of resources
Cost of participant recruitment, education, blood pressure monitors, participant compensation, research coordinator time and cost needed to collect data, and statistical analysis
Time frame: 6 months
Intervention feasibility as measured by sustainability of data collection procedures
Financial and time commitments required to successfully collect participant surveys, blood pressure monitoring results, send information to providers, and monitor provider responses
Time frame: 6 months
Intervention acceptability as measured by qualitative interviews
Qualitative interviews will be performed at the end of the pilot intervention with all study participants to assess the acceptability of the intervention. Rheumatology and primary care providers caring for study participants will also be invited to comment on the acceptability of the intervention.
Time frame: 6 months
Perceived appropriateness of the intervention to address the health care disparity in HTN (hypertension) control for Black RA patients as measured by qualitative interviews
Qualitative interviews will be performed at the end of the pilot intervention with all study participants to assess the perceived appropriateness of the intervention to address the health care disparity in HTN control for Black RA patients. Rheumatology and primary care providers caring for study participants will also be invited to comment on the appropriateness of the intervention.
Time frame: 6 months
Barriers to and enablers of participating in the intervention as measured by qualitative interviews
Qualitative interviews will be performed at the end of the pilot intervention with all study participants to assess barriers to and enablers of participating in the intervention.
Time frame: 6 months
Participant blood pressure values
Systolic and diastolic blood pressures taken at least three times per week and reported to the study team every 2 weeks for 6 months
Time frame: 6 months
Participant rheumatoid arthritis disease activity
Rheumatoid arthritis disease activity self-reported by participants using the RAPID3 score every 2 weeks for 6 months
Time frame: 6 months
Participant medication use
Medication use for hypertension and rheumatoid arthritis reported by participants every 2 weeks for 6 months
Time frame: 6 months
Anti-hypertensive medication adherence
Participant self-reported adherence percentage to anti-hypertensive medications collected every 2 weeks for 6 months
Time frame: 6 months
Perceived barriers to hypertension self-management
Participant self-reported barriers to hypertension self-management collected every 2 weeks for 6 months
Time frame: 6 months
Provider engagement as measured by response to study team messages
Frequency and type of provider responses to study team messages
Time frame: 6 months
Provider engagement as measured by interactions with participants
Frequency and type of provider interactions with participants after receiving a study team message
Time frame: 6 months
Care coordination
Activation of care team members
Time frame: 6 months
Number of participants with a change in medical therapy
Changes in anti-hypertensive or RA therapies
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.